About this Series

Long thought to be a disease of teenagers and young adults, immune thrombocytopenic purpura (ITP) is currently more prevalent in older adults; more than half of ITP patients are over 65, and some are much older. Hemorrhage is the most serious complication, but with long-term, personalized treatment, patients can often achieve lasting remission.

Leading hematologists from Massachusetts General Hospital examine the need for up-to-date guidance on the treatment of ITP, especially with the approvals of novel medical treatments and the decline in the use of splenectomy as a second-line therapy. The physicians also offer strategies for sequencing medications and discuss the need for careful individualization of treatment decisions.

Show More

Who's Who
More on Immune Thrombocytopenic Purpura (ITP)